Teclistamab for multiple myeloma in US hospitals: real-world data analysis

Download video

Teclistamab for multiple myeloma in US hospitals: real-world data analysis

90 views

VJHemOnc – Video Journal of Hematology & HemOnc

11 months ago

Teclistamab for multiple myeloma in US hospitals: real-world data analysis

1:33

Teclistamab for multiple myeloma in US hospitals: real-world data analysis

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Real-world outcomes of teclistamab for R\/R multiple myeloma$

1:43

Real-world outcomes of teclistamab for R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

2:02

Real-World Patient Profile and Dosing of Teclistamab in Myeloma | Carlyn Rose Tan, MD | ASH 2023

by HealthTree Foundation for Multiple Myeloma

$Clinical benefit of teclistamab vs real-world physician’s choice for R\/R multiple myeloma$

1:14

Clinical benefit of teclistamab vs real-world physician’s choice for R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

9:57

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results

by International Myeloma Foundation

$Real-world efficacy \& safety of teclistamab in patients with BCMA-pretreated R\/R multiple myeloma$

1:39

Real-world efficacy \& safety of teclistamab in patients with BCMA-pretreated R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

6:59

Teclistamab in Combination with Sub-Q Daratumumab and Lenalidomide in Myeloma Pts: MajesTEC-2

by International Myeloma Foundation

$Real-world outcomes of teclistamab treatment in R\/R multiple myeloma$

1:50

Real-world outcomes of teclistamab treatment in R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

4:16

What is the monoclonal antibody TALVEY™ (talquetamab)?

by International Myeloma Foundation

2:20

How frequently should TECVAYLI (teclistamab) be given to myeloma patients?

by International Myeloma Foundation

17:55

Talquetamab | Therapies on the horizon #myeloma

by HealthTree University for Multiple Myeloma

5:59

Clinical Outcomes of Teclistamab in the Real World for RRMM | Carlyn Rose Tan, MD | IMS 2024

by HealthTree Foundation for Multiple Myeloma

43:25

The Wales National Multiple Myeloma Dashboard: Providing Visible Real World Data in Haemato-Oncology

by Welsh Value in Health Centre

6:39

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023

by HealthTree Foundation for Multiple Myeloma

$Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R\/R myeloma$

1:27

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R\/R myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Real-world study determining the safety and efficacy of teclistamab in R\/R multiple myeloma$

4:13

Real-world study determining the safety and efficacy of teclistamab in R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Real-world efficacy \& safety of teclistamab in patients with heavily pretreated R\/R multiple myeloma$

6:38

Real-world efficacy \& safety of teclistamab in patients with heavily pretreated R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Evaluating Teclistamab in Relapsed and\/or Refractory Multiple Myeloma$

8:12

Evaluating Teclistamab in Relapsed and\/or Refractory Multiple Myeloma

by International Myeloma Foundation

$Long-term follow-up of real-world teclistamab therapy for R\/R multiple myeloma$

1:24

Long-term follow-up of real-world teclistamab therapy for R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

58:00

Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics

by HealthTree Foundation for Multiple Myeloma

7:25

Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM

by International Myeloma Foundation

1:34

Real-world outcomes of frailty subgroups treated with teclistamab: an IMF study database analysis

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Updated Efficacy\/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022$

11:22

Updated Efficacy\/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022

by International Myeloma Foundation

Best on Vidoe

Teclistamab for multiple myeloma in US hospitals: real-world data analysis